UK-414,495
UK-414,495
UK-414,495 is a pharmaceutical drug candidate that was developed by Pfizer for the treatment of premature ejaculation. The pronunciation of UK-414,495 is "you-kay-four-one-four-four-nine-five". The etymology of the name is based on the naming convention of the company, where "UK" stands for United Kingdom, the location of Pfizer's research facility where the drug was developed, and "414,495" is a unique identifier.
Mechanism of Action
UK-414,495 works by inhibiting the neurotransmitter norepinephrine transporter (NET), thereby increasing the amount of norepinephrine available in the synaptic cleft. This leads to an increase in the duration of sexual intercourse.
Clinical Trials
UK-414,495 has undergone Phase II clinical trials for the treatment of premature ejaculation. However, the development of the drug was discontinued due to adverse side effects.
Related Terms
- Pharmaceutical drug
- Pfizer
- Premature ejaculation
- Neurotransmitter
- Norepinephrine
- Synaptic cleft
- Sexual intercourse
- Phase II clinical trials
External links
- Medical encyclopedia article on UK-414,495
- Wikipedia's article - UK-414,495
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski